Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip J. Mease, Christina Charles‐Schoeman, Stanley Cohen, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 11, pp. 1400-1413
Open Access | Times Cited: 186

Showing 1-25 of 186 citing articles:

The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1487
Management of Rheumatoid Arthritis: An Overview
Andrei-Flavius Radu, Simona Bungău
Cells (2021) Vol. 10, Iss. 11, pp. 2857-2857
Open Access | Times Cited: 638
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 235
Psoriatic arthritis
Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 194
Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
Sarah C. Sasson, Stephanie Slevin, Vincent Cheung, et al.
Gastroenterology (2021) Vol. 161, Iss. 4, pp. 1229-1244.e9
Open Access | Times Cited: 151
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles‐Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 119-129
Open Access | Times Cited: 144
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Christeen Samuel, Hannah Cornman, Anusha Kambala, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 729-749
Open Access | Times Cited: 121
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 335-343
Open Access | Times Cited: 116
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
Léa Hoisnard, Bénédicte Lebrun‐Vignes, Sébastien Maury, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 100
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Léa Hoisnard, Laura Pina Vegas, Rosemary Dray‐Spira, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 182-188
Closed Access | Times Cited: 90
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 706-719
Open Access | Times Cited: 83
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 7, pp. 901-910
Open Access | Times Cited: 79
Nanomedical approaches in the realm of rheumatoid arthritis
Andrei-Flavius Radu, Simona Bungău
Ageing Research Reviews (2023) Vol. 87, pp. 101927-101927
Closed Access | Times Cited: 57
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 54
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Zoltán Szekanecz, Maya H Buch, Christina Charles‐Schoeman, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 101-115
Closed Access | Times Cited: 51
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Paulina Núñez, Rodrigo Quera, Andrés Yarur
Drugs (2023) Vol. 83, Iss. 4, pp. 299-314
Open Access | Times Cited: 48
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, et al.
Annals of the Rheumatic Diseases (2024) Vol. 83, Iss. 6, pp. 760-774
Open Access | Times Cited: 20
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
The safety of JAK-1 inhibitors
Benjamin D Clarke, Mark Yates, Maryam Adas, et al.
Lara D. Veeken (2021) Vol. 60, Iss. Supplement_2, pp. ii24-ii30
Open Access | Times Cited: 93
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review
Peter C. Taylor, Fabiola Atzeni, Alejandro Balsa, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 509-509
Open Access | Times Cited: 81
Cardiovascular effects of approved drugs for rheumatoid arthritis
Fabiola Atzeni, Javier Rodríguez‐Carrio, Călin D. Popa, et al.
Nature Reviews Rheumatology (2021) Vol. 17, Iss. 5, pp. 270-290
Closed Access | Times Cited: 79
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries
Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Thein, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 53, pp. 151979-151979
Closed Access | Times Cited: 68
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 2, pp. 184-192
Open Access | Times Cited: 67
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
Juliana Setyawan, Nassir Azimi, Vibeke Strand, et al.
Drug Safety (2021) Vol. 44, Iss. 8, pp. 889-897
Open Access | Times Cited: 63
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy
Thanigaimalai Pillaiyar, Stefan Laufer
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 955-982
Closed Access | Times Cited: 62
Page 1 - Next Page

Scroll to top